NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) has nominated Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. Dr. Liu, CEO of PAX Therapeutics, is a global expert in vaccines, gene therapy, and cancer immunotherapy. Ms. Naschitz, co-founder of OrbiMed Israel, is a proven life science investor and entrepreneur.
These additions aim to equip Nanobiotix for sustainable long-term growth. Dr. Liu brings experience in academia, pharmaceuticals, biotechnology, and public policy. Ms. Naschitz offers expertise in capital utilization for disruptive innovation. Both nominees have extensive global experience in the biopharmaceutical industry, which is expected to reinforce Nanobiotix's strategic initiatives in oncology for NBTXR3 and expand development opportunities beyond it.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) ha nominato Dr. Margaret A. Liu e Ms. Anat Naschitz come osservatori del suo Consiglio di Supervisione. Il Dr. Liu, CEO di PAX Therapeutics, è un esperto globale in vaccini, terapia genica e immunoterapia contro il cancro. La Ms. Naschitz, co-fondatrice di OrbiMed Israel, è un investitore ed imprenditore affermato nel settore delle scienze della vita.
Queste aggiunte mirano a fornire a Nanobiotix le risorse necessarie per una crescita sostenibile e a lungo termine. Il Dr. Liu porta con sé esperienza nel campo accademico, farmaceutico, biotecnologie e politiche pubbliche. La Ms. Naschitz offre competenze nell'utilizzo del capitale per innovazioni disruptive. Entrambi i candidati hanno una vasta esperienza globale nell'industria biofarmaceutica, che si prevede rafforzerà le iniziative strategiche di Nanobiotix in oncologia per NBTXR3 ed espanderà le opportunità di sviluppo oltre a questo.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) ha nominado a Dr. Margaret A. Liu y Ms. Anat Naschitz como observadores de su Junta de Supervisión. La Dra. Liu, CEO de PAX Therapeutics, es una experta global en vacunas, terapia génica e inmunoterapia contra el cáncer. La Sra. Naschitz, cofundadora de OrbiMed Israel, es una inversionista y empresaria comprobada en ciencias de la vida.
Estas incorporaciones tienen como objetivo preparar a Nanobiotix para un crecimiento sostenible a largo plazo. La Dra. Liu aporta experiencia en academia, farmacéutica, biotecnología y políticas públicas. La Sra. Naschitz ofrece experiencia en la utilización del capital para innovaciones disruptivas. Ambos nominados tienen una amplia experiencia global en la industria biofarmacéutica, lo que se espera refuerce las iniciativas estratégicas de Nanobiotix en oncología para NBTXR3 y amplíe las oportunidades de desarrollo más allá de esto.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX)는 Dr. Margaret A. Liu와 Ms. Anat Naschitz를 감독 위원회 관찰자로 임명했습니다. Liu 박사는 PAX Therapeutics의 CEO로 백신, 유전자 치료 및 암 면역 요법 분야의 세계적인 전문가입니다. Naschitz 씨는 OrbiMed Israel의 공동 창립자로 생명 과학 투자자이자 기업가로서의 경력이 입증되었습니다.
이러한 추가는 Nanobiotix가 지속 가능한 장기 성장을 위한 준비를 하는 것을 목표로 합니다. Liu 박사는 학계, 제약, 생명공학 및 공공 정책 분야에서의 경험을 제공합니다. Naschitz 씨는 파괴적인 혁신을 위한 자본 활용에 대한 전문성을 제공합니다. 두 후보자는 생물 제약 산업에서 폭넓은 글로벌 경험을 보유하고 있으며, 이는 NBTXR3을 위한 Nanobiotix의 전략적 이니셔티브를 강화하고 그 이상의 개발 기회를 확장할 것으로 예상됩니다.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) a nommé Dr. Margaret A. Liu et Ms. Anat Naschitz en tant qu'observateurs au sein de son Conseil de Surveillance. Dr. Liu, PDG de PAX Therapeutics, est une experte mondiale en vaccins, thérapie génique et immunothérapie contre le cancer. Ms. Naschitz, cofondatrice d'OrbiMed Israel, est une investisseuse et entrepreneuse reconnue dans le domaine des sciences de la vie.
Ces ajouts visent à préparer Nanobiotix à une croissance durable à long terme. Dr. Liu apporte son expérience dans le milieu académique, la pharmacie, la biotechnologie et les politiques publiques. Ms. Naschitz offre son expertise en utilisation de capital pour des innovations disruptives. Les deux nominés possèdent une vaste expérience mondiale dans l'industrie biopharmaceutique, ce qui devrait renforcer les initiatives stratégiques de Nanobiotix en oncologie pour NBTXR3 et élargir les opportunités de développement au-delà de cela.
Nanobiotix (Euronext: NANO – NASDAQ: NBTX) hat Dr. Margaret A. Liu und Ms. Anat Naschitz als Beobachter für seinen Aufsichtsrat nominiert. Dr. Liu, CEO von PAX Therapeutics, ist eine globale Expertin für Impfstoffe, Gentherapie und Krebsimmuntherapie. Ms. Naschitz, Mitbegründerin von OrbiMed Israel, ist eine erfahrene Investorin und Unternehmerin im Bereich der Lebenswissenschaften.
Diese Neuzugänge zielen darauf ab, Nanobiotix für nachhaltiges langfristiges Wachstum auszustatten. Dr. Liu bringt Erfahrung aus der Wissenschaft, Pharmazie, Biotechnologie und öffentlichen Politik mit. Ms. Naschitz bietet Fachkenntnisse in der Kapitalnutzung für disruptive Innovationen. Beide Kandidaten haben umfangreiche globale Erfahrungen in der biopharmazeutischen Industrie, die voraussichtlich die strategischen Initiativen von Nanobiotix in der Onkologie für NBTXR3 stärken und die Entwicklungsmöglichkeiten darüber hinaus erweitern werden.
- Addition of two experienced industry experts to the Supervisory Board
- Potential for enhanced strategic guidance in oncology and beyond
- Strengthened expertise in capital utilization and disruptive innovation
- None.
- Dr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boards
- Ms. Anat Naschitz, proven life science investor and entrepreneur; co-founder of OrbiMed Israel
PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board.
“We are thrilled at the opportunity to welcome Ms. Anat Naschitz and Dr. Margaret A. Liu to the Nanobiotix Supervisory Board as we push toward delivering on the practice-changing potential of nanophysics-based therapies for the treatment of cancer and other major diseases,” said Laurent Levy, Ph.D., Nanobiotix Chief Executive Officer and Chairman of the Executive Board. “Dr. Liu brings a wealth of experience in US and international academia, pharmaceuticals, biotechnology and public policy that could prove critical in making the Nanobiotix vision a reality at this important moment in the Company’s history. Ms. Naschitz brings world-class fluency in the language of capital and how that capital can be best utilized to support disruptive innovation for the benefit of patients, healthcare professionals and investors.”
Margaret A. Liu, M.D., is a world-renowned expert in the fields of gene therapy, vaccines and immunotherapy. She currently serves as Chief Executive Officer (“CEO”) of PAX Therapeutics, as an Adjunct Full Professor at the University of California, San Francisco, and as Hedersdoktor with scientific affiliation in the Department of Medicine at the Karolinska Institutet. Dr. Liu pioneered DNA vaccines and bispecific antibodies and has received a number of international awards. Dr. Liu widely consults for companies and scientific governmental and non-governmental organizations such as the World Health Organization (WHO) through her activities as Principal of ProTherImmune and previously held positions of increasing responsibility at Merck & Co. and Chiron Corporation. She is currently a board member of Ipsen, where she chairs the Ethics and Governance Committee and is a member of the Innovation and Development Committee, and as a member of the board, and President Emerita, of the International Society for Vaccines. She also serves on the board of MacroGenics as well as the Science and Technology Committee. Previously she served on the boards of Transgene, Sangamo Biosciences, Adjuvance Technologies and the United Nations Development Programme-established International Vaccine Institute and was Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation. Dr. Liu earned an M.D. from Harvard Medical School and completed an internship and residency in Internal Medicine followed by an Endocrinology Fellowship at Massachusetts General Hospital. She also served on the faculty at Harvard Medical School and was a Visiting Scientist at the Massachusetts Institute of Technology. She obtained a B.A. in Chemistry summa cum laude from Colorado College.
Anat Naschitz is a life science investor and entrepreneur, with over three decades of experience across biotech, pharmaceuticals, computational R&D, digital health and medical devices, in multiple therapy areas and stages. Throughout her career Ms. Naschitz has founded companies and nurtured them through success with public and private board involvement and investment. Currently, she is co-founder and CEO of 9xchange, a computational company creation engine that uses artificial intelligence and machine learning to mine and optimize biopharma assets. Ms. Naschitz co-founded and co-led OrbiMed Israel as part of the ±
“Both Ms. Naschitz and Dr. Liu possess extensive global experience in the biopharmaceutical industry,” said Gary Phillips, M.D, Nanobiotix Supervisory Board chairman. “We expect their expertise to reinforce our ongoing strategic initiatives in oncology for NBTXR3 and expand development and collaboration opportunities for Nanobiotix platforms beyond NBTXR3.”
These nominations will be submitted for ratification at the next Nanobiotix shareholders’ meeting.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024 and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
Attachment
FAQ
Who are the new nominees to Nanobiotix's Supervisory Board?
What is Nanobiotix's stock symbol on NASDAQ?
How might these new board additions benefit Nanobiotix (NBTX)?
When will the nominations of Dr. Liu and Ms. Naschitz be ratified?
